Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy

Pharmacotherapy

Volumn 36, Issue 1, 2016, Pages 99-116

  Jerjian, Taleen V ^a   Glode, Ashley E ^a   Thompson, Lisa A ^a   O'Bryant, Cindy L ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Adcetris; ado trastuzumab emtansine; antibody drug conjugate; brentuximab vedotin; gemtuzumab ozogamicin; Kadcyla; Mylotarg

Indexed keywords

ABIRATERONE; AZACITIDINE; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CAPECITABINE; COLTUXIMAB RAVTANSINE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DOXORUBICIN; ENZALUTAMIDE; ERIBULIN; FLUDARABINE; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; GLEMBATUMUMAB VEDOTIN; INOTUZUMAB OZOGAMICIN; LAPATINIB; MITOXANTRONE; NAVELBINE; PACLITAXEL; PERTUZUMAB; PINATUZUMAB VEDOTIN; POLATUZUMAB VEDOTIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RITUXIMAB; TAXANE DERIVATIVE; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VINBLASTINE; AMINOGLYCOSIDE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; GEMTUZUMAB; MAYTANSINE; MONOCLONAL ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; BLURRED VISION; BRAIN HEMORRHAGE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CAUSE OF DEATH; CONSTIPATION; CYTOGENETICS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FOLLICULAR LYMPHOMA; GASTROINTESTINAL TOXICITY; HEADACHE; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC ENCEPHALOPATHY; HODGKIN DISEASE; HUMAN; HYPOKALEMIA; HYPOTENSION; IN VITRO STUDY; INFECTION; KERATITIS; LARGE CELL LYMPHOMA; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; LUNG HEMORRHAGE; LYMPHOMA; MELANOMA; META ANALYSIS (TOPIC); METABOLIC ENCEPHALOPATHY; MOTOR NEUROPATHY; MUSCULOSKELETAL PAIN; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; OPTIC NERVE DISEASE; OVERALL SURVIVAL; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROMYELOCYTIC LEUKEMIA; RASH; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; REVIEW; STOMACH CANCER; STOMATITIS; SUBARACHNOID HEMORRHAGE; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; VEIN OCCLUSION; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; FEMALE; LEUKEMIA, MYELOID, ACUTE; NEOPLASMS;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOCONJUGATES; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA; MAYTANSINE; NEOPLASMS;

EID: 84960902961     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1687     Document Type: Review

References (77)

1. Teicher BA, Chari RVJ,. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 2011; 17 (20): 6389-97.
2. Zolot RS, Basu S, Million RP,. Antibody-drug conjugates. Nat Rev Drug Discov 2013; 12 (4): 259-60.
3. ® [package insert]. Bothell, WA; 2015.
4. Doronina SO, Toki BE, Torgov MY, et al., Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003; 21 (7): 778-84.
5. ®). National Cancer Institute. Available from http://www.cancer.gov/cancertopics/pdq/treatment/adulthodgkins/HealthProfessional. Accessed January 14, 2015.
6. Younes A, Gopal AK, Smith SE, et al., Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30 (18): 2183-9.
7. Shankland KR, Armitage JO, Hancock BW,. Non-Hodgkin lymphoma. Lancet 2012; 380 (9844): 848-57.
8. Tilly H, Gaulard P, Lepage E, et al., Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood 1997; 90 (9): 3727-34.
9. Smith SM, Burns LJ, van Besien K, et al., Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 2013; 31 (25): 3100-10.
10. Pro B, Advani R, Brice P, et al., Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30 (18): 2190-6.
11. DeVita MD, Evens AM, Rosen ST, Greenberger PA, Petrich AM,. Multiple successful desensitizations to brentuximab vedotin: a case report and literature review. J Natl Compr Canc Netw 2014; 12 (4): 465-71.
12. Younes A, Bartlett NL, Leonard JP, et al., Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363 (19): 1812-21.
13. Adcetris (brentuximab vedotin): drug safety communication-progressive multifocal leukoencephalopathy and pulmonary toxicity. U.S. Food and Drug Administration. Available from http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm287710.htm?source&x003D;govdelivery. Accessed January 14, 2015.
14. Younes A, Connors JM, Park SI, et al., Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol 2013; 14 (13): 1348-56.
15. Moskowitz CH, Nandemanee A, Masszi T, et al., Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 385: 1853-62.
16. Chen R, Palmer JM, Thomas SH, et al., Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012; 119 (26): 6379-81.
17. Chen R, Palmer JM, Tsai NC, et al., Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant 2014; 20 (11): 1841-68.
18. Chen R, Palmer JM, Popplewell L, et al., Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma. Ann Hematol 2011; 90: 803-8. Cited by: Chen R, Palmer JM, Tsai NC, et al. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant 2014;20(11):1841-68.
19. ClinicalTrials.gov website. Available from https://clinicaltrials.gov/. Accessed June 1, 2015.
20. Coussens L, Yang-Feng TL, Liao YC, et al., Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230 (4730): 1132-9.
21. ®). National Cancer Institute. Available from http://www.cancer.gov/cancertopics/pdq/treatment/breast/healthprofessional. Accessed January 14, 2015.
22. National Comprehensive Cancer Network. Breast Cancer (Version 2.2015). Available from http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf. Accessed April 30, 2015.
23. Fountzilas G, Razis E, Tsavdaridis D, et al., Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer 2003; 4 (2): 120-5.
24. Nahta R, Esteva FJ,. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006; 8 (6): 215.
25. Ritter CA, Perez-Torres M, Rinehart C, et al., Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007; 13 (16): 4909-19.
26. ® [package insert]. San Francisco, CA; 2014.
27. Lewis Phillips GD, Li G, Dugger DL, et al., Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68 (22): 9280-90.
28. Junttila TT, Li G, Parsons K, et al., Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011; 128 (2): 347-56.
29. Verma S, Miles D, Gianni L, et al., Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367 (19): 1783-91.
30. Krop IE, Kim SB, González-Martín A, et al., Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15 (7): 689-99.
31. Krop IE, Beeram M, Modi S, et al., Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28 (16): 2698-704.
32. Girish S, Gupta M, Wang B, et al., Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 2012; 69 (5): 1229-40.
33. Perez EA, Hurvitz SA, Amler LC, et al., Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. Breast Cancer Res 2014; 16 (3): R50.
34. Ellis PA, Barrios CH, Eiermann W, et al., Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: primary results from the MARIANNE study [abstract 507]. J Clin Oncol 2015; 33 (Suppl).
35. Hoffmann-La Roche. A study of trastuzumab emtansine (T-DM1) sequentially with anthracycline-based chemotherapy, as adjuvant or neoadjuvant therapy for patients with early stage Herceptin (HER)2-positive breast cancer. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). Available from https://clinicaltrials.gov/ct2/show/NCT01196052 [cited 2015 May 12]. NLM Identifier: NCT01196052, 2000.
36. ®). National Cancer Institute. Available from http://www.cancer.gov/cancertopics/pdq/treatment/adultAML/healthprofessional. Accessed January 14, 2015.
37. ® [package insert]. Philadelphia, PA; 2005.
38. Sievers EL, Larson RA, Stadtmauer EA, et al., Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19 (13): 3244-54.
39. Petersdorf SH, Kopecky KJ, Slovak M, et al., A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013; 121 (24): 4854-60.
40. Rowe JM, Lowenberg B,. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood 2013; 121 (24): 4838-41.
41. Delaunay J, Recher C, Pigneux A, et al., Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogenic transplantation. Results of the GOELAMS AML 2006 IR study [Abstract #79]. Presented at the 53rd American Society of Hematology Annual Meeting and Exposition. San Diego, CA, December 11, 2011.
42. Kharfan-Dabaja MA, Hamadani M, Relijic T, et al., Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol 2013; 163 (3): 315-25.
43. Loke J, Khan JN, Wilson JS, Craddock C, Wheatley K,. Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. Ann Hematol 2015; 94 (3): 361-73.
44. About FDA: Gemtuzumab Ozogamicin. U.S. Food and Drug Administration. Available from http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm216790.htm. Accessed January 30, 2015.
45. Li X, Xu SN, Qin DB, et al., Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials. Ann Oncol 2014; 25 (2): 455-61.
46. Hills RK, Castaigne S, Appelbaum FR, et al., Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 2014; 15 (9): 986-96.
47. Burnett AK, Hills RK, Milligan D, et al., Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011; 29 (4): 369-77.
48. Erba HP,. Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy. Leuk Res 2015; 39 (2): 183-91.
49. Burnett AK, Hills RK, Hunter AE, et al., The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia 2013; 27 (1): 75-81.
50. Nand S, Othus M, Godwin JE, et al., A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood 2013; 122 (20): 3432-9.
51. Amadori S, Suciu S, Stasi R, et al., Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). J Clin Oncol 2013; 31 (35): 4424-30.
52. Chantepie SP, Reboursiere E, Mear JB, et al., Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 2015; 56 (8): 2326-2330; Early Online.
53. O'Hear C, Inaba H, Pounds S, et al., Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer 2013; 119 (22): 4036-43.
54. Gamis AS, Alonzo TA, Meshinchi S, et al., Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531. J Clin Oncol 2014; 32 (27): 3021-32.
55. Breccia M, Lo-Coco F,. Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy. Expert Opin Biol Ther 2011; 11 (2): 225-34.
56. Boué DR, LeBien TW,. Expression and structure of CD22 in acute leukemia. Blood 1988; 71 (5): 1480-6.
57. Litzow MR,. Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book 2013: 294-9.
58. Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, et al., Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 2013; 119 (15): 2728-36.
59. Pfizer phase 3 study of inotuzumab ozogamicin meets primary endpoint in adult patients with relapsed or refractory acute lymphoblastic leukemia. Pfizer Web site. Available from http://www.pfizer.com/news/press-release/press-release-detail/pfizer-phase-3-study-of-inotuzumab-ozogamicin-meets-primary-endpoint-in-adult-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia. Accessed September 22, 2015.
60. Fayad L, Offner F, Smith MR, et al., Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol 2013; 31 (5): 573-83.
61. Coiffier B, Haioun C, Ketterer N, et al., Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92 (6): 1927-32.
62. Wagner-Johnston ND, Goy A, Rodriguez MA, et al., A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma 2015; 56 (10): 2863-9.
63. Advani A, Coiffier B, Czuczman MS, et al., Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010; 28 (12): 2085-93.
64. Loken MR, Shah VO, Dattilio KL, Civin CI,. Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. Blood 1987; 70 (5): 1316-24.
65. Ribrag V, Dupuis J, Tilly H, et al., A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 2014; 20 (1): 213-20.
66. Coiffier B, Thieblemont C, de Guibert S, et al., Phase II study of antiCD19 antibody drug conjugate (SAR3419) in combination with rituximab: clinical activity and safety in patients with relapsed/refractory diffuse large B-Cell lymphoma [abstract 4395]. Presented at the 55th American Society of Hematology Annual Meeting and Exposition. New Orleans, LA, December 9, 2013.
67. Pfeifer M, Zheng B, Erdmann T, et al., Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia 2015; 29 (7): 1578-86.
68. Morschhauser F, Flinn I, Advani RH, et al., Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) [abstract 8519]. J Clin Oncol 2014; 32 (5 Suppl).
69. Tse KF, Jeffers M, Pollack VA, et al., CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 2006; 12 (4): 1373-82.
70. Rose AA, Grosset AA, Dong Z, et al., Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res 2010; 16 (7): 2147-56.
71. Maric G, Rose AA, Annis MG, Siegel PM,. Glycoprotein non-metastatic b (GPNMB): a metastatic mediator and emerging therapeutic target in cancer. Onco Targets Ther 2013; 6: 839-52.
72. Hamid O, Sznol M, Pavlick AC, et al., Frequent dosing and GPNMB expression with CDX011 (CR011vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma [abstract 8525]. J Clin Oncol 2010; 28 (15 Suppl).
73. Burris H, Saleh M, Bendell J, et al., A phase (Ph) I/II study of CR011VcMMAE, an antibody-drug conjugate, in patients (pts) with locally advanced or metastatic breast cancer (MBC) [abstract 6096]. Cancer Res 2009; 69 (24 Suppl).
74. Yardley DA, Weaver R, Melisko ME, et al., A randomized phase 2 study of the antibody-drug conjugate CDX011 in advanced GPNMB-overexpressing breast cancer: the EMERGE study [abstract P6-10-01]. Cancer Res 2012; 72 (24 Suppl).
75. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C,. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3 (1): 81-5.
76. Ross JS, Sheehan CE, Fisher HA, et al., Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003; 9 (17): 6357-62.
77. Petrylak DP, Vogelzang NJ, Chatta GS, et al., A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz) [abstract 144]. J Clin Oncol 2015; 33 (Suppl 7).